- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00846131
Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
13 september 2016 uppdaterad av: Laura Kulik, Northwestern University
A Single-Center Proof of Concept Pilot Study to Evaluate the Safety, Efficacy, and Tolerability of Sorafenib Combined With Therasphere in Subjects With Hepatocellular Carcinoma Awaiting Liver Transplantation.
A research study to determine the safety, efficacy, and tolerability of Therasphere® (also known as Y-90, or Y-90 Therasphere) combined with or without sorafenib (Nexavar®), in patients with hepatocellular carcinoma (HCC, or liver cancer), awaiting liver transplantation.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Because Hepatocellular carcinoma (HCC) grows by forming new blood vessels liver transplant (OLT) offers the best chance for long term survival.
However, with the growing number of patients who require OLT, prolonged wait list times often lead to drop out from the transplant list due to tumor progression.
Some patients are granted an "upgrade",within the generally accepted guidelines for transplant eligibility, in order to expedite the access of patients with early HCC to transplantation before tumor progression.
The use of therapies like radioembolization also known as Yttrium-90 ([Y-90] a procedure where very small beads coated with radiation are injected directly into the tumor through an artery in your groin) while awaiting OLT has become common at most transplant centers, including Northwestern, to help patients reach transplant.
Additionally, these treatments are being used to move patients to a status eligible for transplant.
We are studying whether a combination approach with systemic therapy and therapy applied directly to the liver, will be more successful than a single therapy .
Angiogenesis (a process involving the growth of new blood vessels from pre-existing vessels) plays an important role in the early stages of HCC.
A decrease in angiogenesis both locally within the treated tumor as well as in any existing tumor cells, not yet detected, would hopefully decrease the incidence of post transplant recurrence of HCC.
All subjects enrolled in this study will be treated with the use of Therasphere, Y-90, which is composed of nonbiodegradable glass microspheres coated with the radioactive compound Y-90 which are injected into the hepatic artery.
The concentrated radioactive microspheres within the tumor lead to "inside-out" radiation.
Half of the subjects will be treated with sorafenib (NEXAVAR®) in conjunction with Y-90.
The determination of which subjects will receive sorafenib will be made randomly, like the flip of a coin.
Sorafenib works by slowing the growth of the tumor cell , attacking the tumor from the outside.
Researchers hope to determine whether the subjects treated with sorafenib have an overall improved response to liver directed therapy with Y-90 Therasphere.
Studietyp
Interventionell
Inskrivning (Faktisk)
24
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Northwestern Memorial Hospital
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Adult > 18 years olf of either gender
- Diagnosis of HCC confirmed by biopsy, CT, or MRI
- Able to carry out activities of daily living, awake >50% of waking hours
- Meets eligibility for liver transplantation
- No prior treatment for HCC
- Ability to understand and sign the informed consent
- Child-bearing women and any men agree to use two forms of birth control (one of which should be a barrier method) during the course of therapy and for 8 weeks afterward.
Exclusion Criteria:
- Less than or = 18 years old
- Ineligible for transplant due to comorbid disease
- Renal Failure requiring dialysis of any kind
- Severe Cardiac disease
- History of a stroke
- Evidence of metastatic disease- or tumors that have spread outside the liver
- Known human immunodeficiency virus (HIV) infection
- Uncontrolled blood pressure (systolic > 160) despite medication(s)
- Major surgery within 4 weeks prior to the screening visit
- Active clinically serious infection
- Serious non-healing wound, ulcer, or bone fracture.
- History of gastrointestinal bleeding (GIB) within 6 weeks prior to the screening visit
- Prior transplant of any kind
- Must be able to swallow oral pills, tablets or capsules of any size
- Use of St. John's Wort or rifampin (rifampicin).
- Currently being treated with Interferon and/or Ribavirin therapy due to the thrombocytopenias, lymphopenias and anemias observed with use of these two medications.
- Known or suspected allergy to sorafenib or any agent given in the course of this trial.
- Any malabsorption problem
- Pregnancy or lactation. Women of childbearing potential must have a negative pregnancy test 7 days prior to beginning therapy.
- No potential living donor transplant (LDT-donor identified and worked up by the time of randomization into this study. If a living donor is later identified- the subject will be allowed to continue in the study. Sorafenib will be stopped at a minimum of 7 days prior to transplant surgery.
- Active alcohol use, drug use, or a psychiatric disease that would, in the opinion of the PI or a subinvestigator (sub-I), prevent the subject from complying with the study protocol and/or endanger the subject during their participation in the study
- Inability of the potential subject to read, understand and sign the informed consent document
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: A: Y-90 alone
Patients randomized to Arm A will proceed to Y-90 treatment alone in the Northwestern standard of care procedure
|
Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
Andra namn:
|
Experimentell: B: Sorafenib + Y-90
Patients randomized to Arm B will start sorafenib at a dose of 400 mg twice daily for bilirubin ≤ 1.5 x ULN and 200 mg twice daily for bilirubin > 1.5 x ULN to ≤ 3 x ULN.
After 14 days of sorafenib therapy (+/- 3 days) patients will proceed to Y-90 in the Northwestern standard of care procedure
|
Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
Andra namn:
Randomized to Y-90 ± Sorafenib
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
To Evaluate sorafenib as an adjunct to Y-90 for control of HCC as a bridge/downstage to transplant
Tidsram: Up to one year
|
Subjects randomized to receive Sorafenib take the drug for 2 weeks before treatment with Y90.
They have imaging (CT/MRI) 2 weeks after starting Sorafenib then are treated.
Post-treatment patients have blood drawn and adverse event evaluation at 2 weeks, 4 weeks, 6 weeks, and then every 6 weeks up to 1 year or time of transplant.
Repeat imaging is done at 4 weeks, and then every 3 months post-treatment.
Subjects not receiving Sorafenib are treated with Y90 and then are evaluated post-treatment the same as the subjects that receive the drug.
|
Up to one year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
To characterize the toxicity profile of sorafenib and Y90 using NCI CTC toxicity grading scales.
Tidsram: up to 1 year
|
Subjects randomized to receive Sorafenib take the drug for 2 weeks before treatment with Y90.
They have imaging (CT/MRI) 2 weeks after starting Sorafenib then are treated.
Post-treatment patients have blood drawn and adverse event evaluation at 2 weeks, 4 weeks, 6 weeks, and then every 6 weeks up to 1 year or time of transplant.
Repeat imaging is done at 4 weeks, and then every 3 months post-treatment.
Subjects not receiving Sorafenib are treated with Y90 and then are evaluated post-treatment the same as the subjects that receive the drug.
|
up to 1 year
|
To identify predictive and prognostic markers of how the liver cancer will respond to treatment.
Tidsram: up to 1 year
|
All subjects are evaluated with lab work and adverse event assessment at 2, 4, and 6 weeks post-treatment, and then every 6 weeks up to 1 year or when they receive transplant.
|
up to 1 year
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Laura Kulik, MD, Northwestern University, Northwestern Memorial Hospital, Northwestern Medical Faculty Foundation
- Huvudutredare: Riad Salem, MD, Northwestern University, Northwestern Memorial Hospital, Northwestern Medical Faculty Foundation
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014 Aug;61(2):309-17. doi: 10.1016/j.jhep.2014.03.023. Epub 2014 Mar 27.
- Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 +/- sorafenib. Hepatology. 2013 Nov;58(5):1655-66. doi: 10.1002/hep.26487. Epub 2013 Oct 1.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 februari 2009
Primärt slutförande (Faktisk)
1 juli 2015
Avslutad studie (Faktisk)
1 september 2016
Studieregistreringsdatum
Först inskickad
16 februari 2009
Först inskickad som uppfyllde QC-kriterierna
17 februari 2009
Första postat (Uppskatta)
18 februari 2009
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
15 september 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
13 september 2016
Senast verifierad
1 september 2016
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neoplasmer efter plats
- Adenocarcinom
- Neoplasmer, körtel och epitel
- Neoplasmer i matsmältningssystemet
- Leversjukdomar
- Neoplasmer i levern
- Carcinom
- Karcinom, hepatocellulärt
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Proteinkinashämmare
- Sorafenib
Andra studie-ID-nummer
- NU08I4
- STU00005761 (Annan identifierare: Northwestern University IRB)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hepatocellulärt karcinom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeOral Cavity Carcinom | Oral intraepitelial neoplasiFörenta staterna
-
Endo PharmaceuticalsAvslutad
-
Indira Gandhi Medical College, ShimlaOkänd
-
Ontario Clinical Oncology Group (OCOG)Avslutad
-
Washington University School of MedicineAvslutad
-
Stanford UniversityAvslutad
-
BayerAmgenAvslutadCarcinomFörenta staterna
-
Centre Leon BerardAvslutad
-
Yueyong XiaoOkänd
Kliniska prövningar på Yttrium-90 (Y-90)
-
Emory UniversityNational Cancer Institute (NCI); Sirtex MedicalIndragenAnatomisk steg IV bröstcancer AJCC v8 | Prognostisk steg IV bröstcancer AJCC v8 | Metastaserande bröstkarcinom | Metastaserande karcinom i levernFörenta staterna
-
OHSU Knight Cancer InstituteOregon Health and Science University; Boston Scientific CorporationAvslutad
-
Massachusetts General HospitalNational Institutes of Health (NIH); Implant SciencesAvslutadSpinala neoplasmerFörenta staterna
-
M.D. Anderson Cancer CenterSirtex MedicalRekrytering
-
GrandPharma (China) Co., Ltd.Har inte rekryterat ännu
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology och andra samarbetspartnersIndragenHepatocellulärt karcinom | Steg III hepatocellulärt karcinom AJCC v8 | Steg IIIA hepatocellulärt karcinom AJCC v8 | Steg IVA hepatocellulärt karcinom AJCC v8 | Steg IIIB hepatocellulärt karcinom AJCC v8 | Steg IB hepatocellulärt karcinom AJCC v8 | Steg II hepatocellulärt karcinom AJCC v8 | Steg I hepatocellulärt... och andra villkorFörenta staterna
-
Sirtex MedicalBright Research PartnersRekryteringOoperabelt hepatocellulärt karcinom | BCLC Steg B Hepatocellulärt karcinom | BCLC Steg C Hepatocellulärt karcinom | BCLC Steg A Hepatocellulärt karcinomFörenta staterna
-
H. Lee Moffitt Cancer Center and Research InstituteBTG International Inc.AvslutadKolangiokarcinomFörenta staterna
-
Thomas Jefferson UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Aktiv, inte rekryterandeHepatocellulärt karcinomFörenta staterna
-
University of Michigan Rogel Cancer CenterDepartment of Health and Human Services; National Institute for Biomedical...Rekrytering